



44862 / 00001

/ Ipw  
PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Jose Andres Morales Garzon et al.

Serial No.: 10/695,104

Filed: October 28, 2003

Confirmation No.: 4820

Group: 1648

Examiner: Ali Reza Salimi

For:  
  
PREVENTION AND TREATMENT OF THE PORCINE  
REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS)  
USING IMMUNOGLOBULINS OBTAINED FROM EGG  
YOLK FROM HENS HYPERIMMUNIZED WITH THE PRRS  
VIRUS

07/07/2005 HTECKLU1 00000017 10695104

01 FC:1806

180.00 OP

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that the papers enclosed herein are being deposited with the United States Postal Service, via first class mail with sufficient postage, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450:

6/30/05

Date of Deposit

Dear Sirs:

**FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §1.56, Applicants submit this First Supplemental Information Disclosure Statement to provide copies of references cited by the Examiner in co-pending application no. 10/803,609. This submittal is made in accordance with 37 C.F.R. §§1.97 and 1.98 and §609 of the Manual of Patent Examining Procedure. More particularly, this submittal is made in accordance with 37 C.F.R. §1.97(c) and is accompanied by the fee as set forth in §1.17(p). The patents, publications and other information herein are listed

on the attached Form PTO/SB/08A and B. Copies of the non-patent literature references are submitted herewith.

Applicant hereby expressly reserves the right to swear behind the effective dates of any of the above patents and other publications and to question the relevance and materiality of the patents and other publications listed herein, in whole, in part, or in combination, subsequent to filing this second supplemental First Supplemental Information Disclosure Statement.

The Commissioner is hereby authorized to charge any additional fee or credit any overpayment due to Locke Liddell & Sapp LLP Deposit Account No. 12-1781.


| Respectfully submitted,

By: \_\_\_\_\_

  
Kristen R. Paris  
Registration No. 52,092

Date: June 30, 2005

LOCKE LIDDELL & SAPP LLP  
2200 Ross Avenue, Suite 2200  
Dallas, TX 75201-6776  
(214) 740-8678  
(214) 740-8800 (fax)



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

Approved for use through 07/07/2008. GPO 2007-088.

**U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE**

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

## ~~Substitute for form~~

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

Sheet 1 of 2

**Complete if Known**

Application Number	10/695,104
Filing Date	October 28, 2003
First Named Inventor	Garzon
Art Unit	1648
Examiner Name	Ali Reza Salimi

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
				Application Number	10/695,104
				Filing Date	October 28, 2003
				First Named Inventor	Garzon
				Art Unit	1648
				Examiner Name	Ali Reza Salimi
Sheet	2	of	2	Attorney Docket Number	44862 / 00001

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	1	CONVERSE, K. et al., Screening for potential human pathogens in fecal material deposited by resident Canada geese on areas of public utility, (cont'd)			
		National Wildlife Health Center, 1999, <a href="http://www.nwhc.usgs.gov/pub_metadata/canada_geese.html">www.nwhc.usgs.gov/pub_metadata/canada_geese.html</a>			
	2	FRIEND, M. et al., Intestinal Coccidiosis, Field Manual of Wildlife Diseases: Birds, chapter 26, pp. 207-214			
	3	KASHALA, O. et al., Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with (cont'd)			
		the immunological adjuvant QS-21, Vaccine, 2002, vol. 20, pp. 2263-2277			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.